Yazan S Khaled

Dr. Yazan S Khaled

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
BCBelal Chaudhary
Belal Chaudhary
YKYazan S Khaled
Yazan S Khaled
BABasil J. Ammori
Basil J. Ammori
Eyad ElkordEyad Elkord
Eyad Elkord

25 June 2013 in Immunology & Cell Biology
Verified
Journal Article
Closed access
YKYazan S Khaled
Yazan S Khaled
BABasil J Ammori
Basil J Ammori
Eyad ElkordEyad Elkord
Eyad Elkord

29 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
YKYazan S Khaled
Yazan S Khaled
BABasil J. Ammori
Basil J. Ammori
Eyad ElkordEyad Elkord
Eyad Elkord
Pancreatic cancer (PC) often presents late with poor survival. While role of immunosuppressive cells in preclinical studies provided help to develop immunotherapeutic agents, these cells remain under investigation in PC. The aim of this study was to characterise the different subsets of myeloid-derived suppressor cells (MDSCs) and evaluate their level and function in the circulation and tissue of PC patients. Significant increases in circulating and tumour-infiltrating granulocytic (Lin-HLA-DR-CD33+CD11b+CD15+), but not monocytic (Lin-HLA-DR-CD14+), MDSCs were detected in PC patients when compared with healthy donors and patients with chronic pancreatitis. The circulating MDSCs from PC patients expressed arginase 1, which represents their functional state. Blood levels of MDSCs showed no association with PC stage or preoperative levels of tumour markers. These findings provide a first characterisation of the phenotype of different subsets of peripheral and local MDSCs in PC patients and suggest that the frequency and contribution of these cells are predominantly granulocytic. This information demonstrates that MDSCs play a role in pancreatic cancer and future large validation studies may help in the development of new immunotherapeutic strategies to inhibit or eliminate MDSC function.

23 February 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
APArindam Pramanik
Arindam Pramanik
ZXZexi Xu
Zexi Xu
SSShazana Hilda Shamsuddin
Shazana Hilda Shamsuddin
YKYazan S Khaled
Yazan S Khaled
NINicola Ingram
Nicola Ingram
PMPaul Millner
Paul Millner
Nanomedicines, while having been approved for cancer therapy, present many challenges such as low stability, rapid clearance, and nonspecificity leading to off-target toxicity. Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles; however, their behavior in vivo is largely underexplored, hindering clinical translation. Here, we have engineered cubosomes based on the space group Im3m that are loaded with copper acetylacetonate as a model drug, and their surfaces are functionalized for the first time with Affimer proteins via copper-free click chemistry to actively target overexpressed carcinoembryonic antigens on LS174T colorectal cancer cells. Unlike nontargeted cubosomes, Affimer tagged cubosomes showed preferential accumulation in cancer cells compared to normal cells not only in vitro (2D monolayer cell culture and 3D spheroid models) but also in vivo in colorectal cancer mouse xenografts, while exhibiting low nonspecific absorption and toxicity in other vital organs. Cancerous spheroids had maximum cell death compared to noncancerous cells upon targeted delivery. Xenografts subjected to targeted drug-loaded cubosomes showed a 5–7-fold higher drug accumulation in the tumor tissue compared to the liver, kidneys, and other vital organs, a significant decrease in tumor growth, and an increased survival rate compared to the nontargeted group. This work encompasses the first thorough preclinical investigation of Affimer targeted cubosomes as a cancer therapeutic.

30 May 2013 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
YKYazan S Khaled
Yazan S Khaled
DMDeep J. Malde
Deep J. Malde
CSCiaran de Souza
Ciaran de Souza
AKAmun Kalia
Amun Kalia
BABasil J. Ammori
Basil J. Ammori

11 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMay Abd Al Samid
May Abd Al Samid
BCBelal Chaudhary
Belal Chaudhary
YKYazan S Khaled
Yazan S Khaled
BABasil J. Ammori
Basil J. Ammori
Eyad ElkordEyad Elkord
Eyad Elkord
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients